Next Article in Journal
Illustrating and Enhancing the Biosynthesis of Astaxanthin and Docosahexaenoic Acid in Aurantiochytrium sp. SK4
Previous Article in Journal
Synthesis and Evaluation of a Chitosan Oligosaccharide-Streptomycin Conjugate against Pseudomonas aeruginosa Biofilms
Previous Article in Special Issue
Reduced Number of Adipose Lineage and Endothelial Cells in Epididymal fat in Response to Omega-3 PUFA in Mice Fed High-Fat Diet
Article Menu

Export Article

Open AccessArticle
Mar. Drugs 2019, 17(1), 44;

Inhibition of Adipogenesis by Diphlorethohydroxycarmalol (DPHC) through AMPK Activation in Adipocytes

Department of Marine Life Sciences, Jeju National University, Jeju 63243, Korea
Korea Food Research Institute, 245 Nongsaengmyeong-Ro Iseo-Myeon, Wanju-Gun, Jeollabuk-Do 55365, Korea
Department of Pharmaceutical Engineering, Soonchunhyang University, Asan 31538, Korea
These authors contributed equally to this study.
Author to whom correspondence should be addressed.
Received: 3 December 2018 / Revised: 29 December 2018 / Accepted: 7 January 2019 / Published: 10 January 2019
(This article belongs to the Special Issue Marine Natural Products and Obesity)
Full-Text   |   PDF [996 KB, uploaded 10 January 2019]   |  
  |   Review Reports


The purpose of this study was to investigate the antiobesity effect and the mechanism of action of diphlorethohydroxycarmalol (DPHC) isolated from Ishige okamurae in 3T3-L1 cells. The antiobesity effects were examined by evaluating intracellular fat accumulation in Oil Red O-stained adipocytes. Based on the results, DPHC dose-dependently inhibited the lipid accumulation in 3T3-L1 adipocytes. DPHC significantly inhibited adipocyte-specific proteins such as SREBP-1c, PPARγ, C/EBP α, and adiponectin, as well as adipogenic enzymes, including perilipin, FAS, FABP4, and leptin in adipocytes. These results indicated that DPHC primarily acts by regulating adipogenic-specific proteins through inhibiting fat accumulation and fatty acid synthesis in adipocytes. DPHC treatment significantly increased both AMPK and ACC phosphorylation in adipocytes. These results indicate that DPHC inhibits the fat accumulation by activating AMPK and ACC in 3T3-L1 cells. Taken together, these results suggest that DPHC can be used as a potential therapeutic agent against obesity. View Full-Text
Keywords: adipogenesis; antiobesity; adipocytes; diphlorethohydroxycarmalol (DPHC) adipogenesis; antiobesity; adipocytes; diphlorethohydroxycarmalol (DPHC)

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Kang, M.-C.; Ding, Y.; Kim, H.-S.; Jeon, Y.-J.; Lee, S.-H. Inhibition of Adipogenesis by Diphlorethohydroxycarmalol (DPHC) through AMPK Activation in Adipocytes. Mar. Drugs 2019, 17, 44.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top